Shares of Beigene Ltd (NASDAQ:BGNE) have received a consensus broker rating score of 1.17 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and two have assigned a strong buy rating to the company.
Brokerages have set a one year consensus target price of $43.00 for the company and are anticipating that the company will post ($0.72) earnings per share for the current quarter, according to Zacks. Zacks has also given Beigene an industry rank of 102 out of 265 based on the ratings given to related companies.
Several equities research analysts recently commented on BGNE shares. Zacks Investment Research upgraded shares of Beigene from a “sell” rating to a “hold” rating in a research report on Tuesday, July 19th. Cowen and Company restated a “buy” rating on shares of Beigene in a research report on Monday, June 6th. Finally, Maxim Group restated a “buy” rating and issued a $41.00 price target on shares of Beigene in a research report on Wednesday.
Beigene (NASDAQ:BGNE) opened at 30.98 on Monday. The firm’s market cap is $1.02 billion. Beigene has a one year low of $22.51 and a one year high of $35.60. The company’s 50-day moving average is $29.30 and its 200 day moving average is $28.99.
Beigene (NASDAQ:BGNE) last posted its earnings results on Wednesday, August 10th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.05. The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $2.08 million. The business’s quarterly revenue was down 71.4% compared to the same quarter last year. Equities analysts anticipate that Beigene will post ($3.45) earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Hillhouse Capital Management Ltd. bought a new stake in Beigene during the first quarter valued at $20,517,000. FMR LLC raised its stake in Beigene by 34.0% in the second quarter. FMR LLC now owns 2,300,337 shares of the company’s stock valued at $68,550,000 after buying an additional 583,277 shares in the last quarter. Temasek Holdings Private Ltd bought a new stake in Beigene during the first quarter valued at $11,138,000. VHCP Management II LLC bought a new stake in Beigene during the first quarter valued at $3,488,000. Finally, Boxer Capital LLC raised its stake in Beigene by 18.4% in the second quarter. Boxer Capital LLC now owns 493,630 shares of the company’s stock valued at $14,710,000 after buying an additional 76,751 shares in the last quarter.
Beigene Company Profile
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.